Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.

[1]  K. Brew,et al.  Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. , 2008, Biochemical and biophysical research communications.

[2]  B. Têtu,et al.  Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. , 2008, American journal of clinical pathology.

[3]  Bernd R Binder,et al.  uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s view , 2007, Thrombosis and Haemostasis.

[4]  A. Godwin,et al.  Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis , 2007, Molecular carcinogenesis.

[5]  Jiahong Dong,et al.  Interaction between Cancer Cells and Stromal Fibroblasts Is Required for Activation of the uPAR-uPA-MMP-2 Cascade in Pancreatic Cancer Metastasis , 2006, Clinical Cancer Research.

[6]  Yong Li,et al.  Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. , 2006, Human pathology.

[7]  I. Christensen,et al.  Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC) , 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[8]  S. Bhoola,et al.  Diagnosis and Management of Epithelial Ovarian Cancer , 2006, Obstetrics and gynecology.

[9]  A. Perkins,et al.  Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. , 2006, Cancer letters.

[10]  Liz Y. Han,et al.  The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer , 2006, Clinical Cancer Research.

[11]  N. Brünner,et al.  A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. , 2005, Gynecologic oncology.

[12]  D. Montell,et al.  Ovarian Cancer Metastasis: Integrating insights from disparate model organisms , 2005, Nature Reviews Cancer.

[13]  Hayley Morgan,et al.  Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity , 2005, Cancer Cell International.

[14]  D. Fishman,et al.  Proinvasive Properties of Ovarian Cancer Ascites-Derived Membrane Vesicles , 2004, Cancer Research.

[15]  Y. Song,et al.  Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. , 2004, Gynecologic oncology.

[16]  P. Torng,et al.  Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. , 2004, Gynecologic oncology.

[17]  M. Fernö,et al.  High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer , 2003, International journal of cancer.

[18]  F. Blasi,et al.  The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy , 2003, Cancer and Metastasis Reviews.

[19]  Maria Pavlaki,et al.  Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials , 2003, Cancer and Metastasis Reviews.

[20]  Stefania Forti,et al.  New insights into the role of extracellular matrix during tumor onset and progression , 2002, Journal of cellular physiology.

[21]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[22]  E. Lengyel,et al.  Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  K. Hess,et al.  Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Rosemurgy,et al.  Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Kimmig,et al.  Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  C. Borgfeldt,et al.  Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI‐1) , 2001, International journal of cancer.

[27]  A. Krüger,et al.  The urokinase plasminogen activator system as a novel target for tumour therapy , 2000 .

[28]  N. Brünner,et al.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. , 2000, Cancer research.

[29]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[30]  H. Höfler,et al.  Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc , 1999, British Journal of Cancer.

[31]  H. Chapman,et al.  A Role for Caveolin and the Urokinase Receptor in Integrin-mediated Adhesion and Signaling , 1999, The Journal of cell biology.

[32]  C. Borgfeldt,et al.  High tissue content of urokinase plasminogen activator (u‐PA) is associated with high stromal expression of u‐PA mRNA in poorly differentiated serous ovarian carcinoma , 1998, International journal of cancer.

[33]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[34]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[35]  J. Foekens,et al.  Expression of urokinase‐type plasminogen activator (uPA) and its inhibitor PAI‐1 in benign, borderline, malignant primary and metastatic ovarian tumors , 1996, International journal of cancer.

[36]  A. Aasen,et al.  Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. , 1995, Human pathology.

[37]  J. Becker,et al.  Anti-cancer therapies targeting the tumor stroma , 2007, Cancer Immunology, Immunotherapy.

[38]  M. Duffy,et al.  The urokinase plasminogen activator system: role in malignancy. , 2004, Current pharmaceutical design.

[39]  Andy H. Lee,et al.  Reproductive and dietary risk factors for epithelial ovarian cancer in China. , 2004, Gynecologic oncology.

[40]  B. Casslén,et al.  Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. , 1994, European journal of cancer.